- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298477
EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study (EVAS2)
March 7, 2024 updated by: Endologix
Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix System IDE Study (EVAS 2 Confirmatory IDE Study)
Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site.
All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the safety and effectiveness of the Nellix System among a wide range of physicians and in consecutively enrolled subjects to assess safety and effectiveness outcomes.
Following appropriate government and ethics committee/IRB approval the Nellix® EndoVascular Sealing System will be implanted into eligible patients who are adequately informed and have consented to join the study.
Enrolled patients will undergo a high resolution, contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and aortoiliac vasculature within three months of the scheduled procedure and at specified follow-up intervals post-implantation.
Follow-up visits will occur at 30 days, 6 months, and annually to 5 years to assess aneurysm morphology, the status of the implanted devices, and relevant laboratory test results.
Study Type
Interventional
Enrollment (Actual)
98
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Valley Vascular Consultants
-
-
California
-
Los Angeles, California, United States, 90095
- Regents of the University of California (UCLA)
-
San Diego, California, United States, 92161
- Veterans Medical Research Foundation
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- UC Health-Memorial Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Health Research Institute
-
-
Florida
-
Miami, Florida, United States, 33176
- Miami Cardiac & Vascular Institute (MCVI)
-
Orlando, Florida, United States, 32803
- AdventHealth Orlando
-
Pensacola, Florida, United States, 32503
- Coastal Vascular & Interventional
-
-
Illinois
-
Champaign, Illinois, United States, 61820
- Christie Clinic
-
Elk Grove Village, Illinois, United States, 60007
- AMITA Health
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- St. Vincent Heart Center of Indiana
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Bay City, Michigan, United States, 48708
- McLaren Bay Region
-
-
Missouri
-
Kansas City, Missouri, United States, 64116
- Midwest Aortic & Vascular Institute
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- The Cooper Health System
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- New Mexico Heart Institute
-
-
New York
-
New York, New York, United States, 10029
- ICAHN School of Medicine at Mount Sinai
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Willoughby, Ohio, United States, 44095
- Northeast Ohio Vascular Assoc (NEOVA)
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74135
- OU College of Medicine
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence St. Vincent Medical Center
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Palmetto Health- University of South Carolina
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
- Wellmont CVA Heart Institute
-
Memphis, Tennessee, United States, 38120
- Cardiovascular Surgery Clinic
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Research Center
-
-
Washington
-
Spokane, Washington, United States, 99204
- Providence Sacred Heart Medical Center
-
-
Wisconsin
-
Wausau, Wisconsin, United States, 54401
- Aspirus Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
INCLUSION CRITERIA
A patient who meets all of the following criteria potentially may be included in the study:
- Male or female at least 18 years old;
- Informed consent form understood and signed
- Patient agrees to all follow-up visits;
- Abdominal aortic aneurysm with sac diameter ≥5.0cm, or ≥4.5cm which has increased by ≥0.5cm within the last 6 months, or or which exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment. No AAA <4 cm will be included.
Anatomically eligible for the Nellix System (per Instructions For Use):
- Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥6 mm);
- Aneurysm blood lumen diameter ≤60mm;
- Proximal non-aneurysmal aortic neck: length ≥10mm; diameter 18 to 28mm; angle ≤60° to the aneurysm sac;
- Most caudal renal artery to each hypogastric artery length ≥100mm;
- Common iliac artery lumen diameter between 9 and 35mm;
- Distal iliac artery seal zone with length of ≥10mm and diameter range of 9 to 25mm;
- Ability to preserve at least one hypogastric artery.
- Ratio of maximum aortic aneurysm diameter to maximum aortic blood lumen diameter <1.40
EXCLUSION CRITERIA
A patient who meets none of the following criteria potentially may be included in the study:
- Life expectancy <2 years as judged by the Investigator;
- Psychiatric or other condition that may interfere with the study;
- Participating in another clinical study;
- Known allergy or contraindication to any device material;
- Coagulopathy or uncontrolled bleeding disorder;
- Ruptured, leaking or mycotic aneurysm;
- Serum creatinine (S-Cr) level >2.0 mg/dL;
- CVA or MI within three months of enrollment/treatment;
- Aneurysmal disease of the descending thoracic aorta;
- Clinically significant mural thrombus within the proximal landing zone (minimum 10mm) of the infrarenal non-aneurysmal neck (>5mm thickness over >50% circumference);
- Connective tissue diseases (e.g., Marfan Syndrome);
- Unsuitable vascular anatomy that may interfere with device introduction or deployment;
- Pregnant (female of childbearing potential only).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single Arm
Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
|
Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Major Adverse Events (MAE)
Time Frame: 30 days
|
All cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, procedural blood loss >1,000cc
|
30 days
|
Rate of Treatment Success
Time Frame: 1 year
|
Procedural technical success and the absence of aneurysm rupture, conversion to open surgical repair, Type I endoleak at 12 months, Type III endoleak at 12 months, aneurysm enlargement, secondary procedure for resolution of endoleak (Type I or III), limb occlusion, migration, aneurysm sac expansion and/or a device defect
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey Carpenter, MD, Cooper Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2017
Primary Completion (Actual)
June 7, 2022
Study Completion (Estimated)
August 16, 2025
Study Registration Dates
First Submitted
September 27, 2017
First Submitted That Met QC Criteria
September 27, 2017
First Posted (Actual)
October 2, 2017
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-0008 EVAS2 IDE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm Without Rupture
-
Rede Optimus Hospitalar SAShockwave Medical, Inc.Not yet recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm Without Rupture | Thoracic Aortic Aneurysm Without Rupture
-
Dr. Sabrina OverhagenActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Karolinska University HospitalMedical University of Graz; St. Olavs HospitalCompletedAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Imperial College LondonThe British Society of Endovascular Therapy (BSET)CompletedAbdominal Aortic Aneurysm Without RuptureUnited Kingdom
-
Hospital Sao JoaoCompletedAbdominal Aortic Aneurysm Without RupturePortugal
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Nano4Imaging GmbH; BrightfishRecruitingAbdominal Aortic Aneurysm Without RuptureNetherlands
-
Imperial College LondonW.L.Gore & Associates; MedtronicNot yet recruiting
-
Centre hospitalier de l'Université de Montréal...McGill University; University of Calgary; Eindhoven University of TechnologyRecruitingAbdominal Aortic Aneurysm Without RuptureCanada
-
Hangzhou Endonom Medtech Co., Ltd.UnknownJuxta Renal Abdominal Aortic Aneurysm Without RuptureChina
Clinical Trials on Nellix® System
-
EndologixActive, not recruitingAbdominal Aortic AneurysmNew Zealand, Spain, Germany, Netherlands
-
EndologixCompletedAbdominal Aortic AneurysmsNew Zealand, Colombia, Latvia, Venezuela
-
EndologixCompletedAbdominal Aortic Aneurysm (AAA)United States, United Kingdom, Germany, Netherlands
-
Rijnstate HospitalCompletedAbdominal Aortic Aneurysm | Endovascular Aortic Repair | Nellix Endovascular Sealing
-
Rijnstate HospitalCompleted
-
Rijnstate HospitalCompleted
-
CVRx, Inc.Completed
-
Prof. Dr. Carsten PerkaJulius Wolff InstituteUnknown
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...TerminatedPilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating HydrocephalusHydrocephalus | Hydrocephalus, CommunicatingUnited States
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States